Last Updated:
Unlisted shares of Senores Pharmaceuticals Ltd are currently trading at Rs 631 per share in the grey market, which is 61.38 per cent higher than the IPO issue price of Rs 391. It indicates a stellar listing on December 30.
Senores Pharmaceuticals IPO.
Senores Pharmaceuticals IPO Allotment Status: The allotment of the Senores Pharmaceuticals IPO will be finalised today in the evening (December 26). The initial public offering of Senores Pharmaceuticals Ltd closed on Tuesday and received an overall 97.86 times subscription. The Senores Pharmaceuticals IPO listing will take place on Monday, December 30. The latest GMP currently stands at 61.38 per cent, signalling a robust listing.
The initial public offering of Senores Pharmaceuticals Ltd, which was opened on between December 20 and December 24, received an overall 97.86 times subscription. The retail category recieved a 93.16 times subscription in total, the NII (non-institutional investors) portion got 100.35 times subscription. Its QIB (qualified institutional buyer) category has been subscribed by 97.84 times.
The price band of the IPO was fixed at Rs 372 to Rs 391 apiece.
The shares of Senores Pharmaceuticals Ltd are scheduled to be listed on both BSE and NSE on December 30, Monday.
The IPO allotment will be finalised on the Thursday evening. Once allotted, investors will receive a bank debit message. They can also check the IPO allotment status on the websites of BSE and NSE, as well as on registrar Link Intime’s portal.
Senores Pharmaceuticals IPO GMP Today
According to market observers, unlisted shares of Senores Pharmaceuticals Ltd are currently trading at Rs 631 per share in the grey market, which is Rs 240 or 61.38 per cent higher than the IPO issue price of Rs 391. It indicates a stellar listing on December 30.
The GMP is based on market sentiments and keeps changing. ‘Grey market premium’ indicates investors’ readiness to pay more than the issue price.
Senores Pharmaceuticals IPO: How To Check Allotment Status Online?
The IPO allotment status can be checked online by following these steps:
1) Go to the official BSE website via the URL —https://www.bseindia.com/investors/appli_check.aspx.
2) Under ‘Issue Type’, select ‘Equity’.
3) Under ‘Issue Name’, select ‘Senores Pharmaceuticals Ltd’ in the dropbox.
4) Enter your application number, or the Permanent Account Number (PAN).
5) Then, click on the ‘I am not a robot’ to verify yourself and hit ‘Search’ option.
Your share application status will appear on your screen.
You can also visit direct Link Intime Ltd’s portal — and check the Senores Pharmaceuticals IPO allotment status.
Senores Pharmaceuticals IPO: More Details
The Ahmedabad-based company’s IPO is a combination of fresh issuance of shares worth Rs 500 crore and an offer-for-sale (OFS) of up to 21 lakh shares valued Rs 82.11 crore, by promoters and other selling shareholders, at the upper-end of the price band.
Senores Pharmaceuticals Ltd has secured nearly Rs 261 crore from anchor investors.
Proceeds from the fresh issue will be utilised for setting up a manufacturing facility for production of sterile injections in its Atlanta facility; funding the working capital requirements of the company and its subsidiaries, supporting inorganic growth through acquisition and other strategic initiatives and payment of debt. Besides, a portion will be used for general corporate purposes.
Senores Pharmaceuticals specialises in identifying, developing, and manufacturing a wide array of specialty, underserved, and complex pharmaceutical products, positioning itself as a preferred partner for select customers.
The company has several products in major therapeutic segments, including antibiotics, anti-bacterial, anti-fungal, and blood lines.
As of March 2024, the company had three R&D facilities in India and the US and is in the process of consolidating R&D facilities into one proposed dedicated facility in Ahmedabad.
Equirus Capital, Ambit, and Nuvama Wealth Management are the book running lead managers to the issue.
The equity shares are proposed to be listed on the BSE and the NSE.
